市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | ProKidney Corp. | 混合的 | 看涨 |
AIStockmoo 评分
-0.8
| 分析师共识 | NA |
| 内部交易活动 | -3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.75 |
|
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 30.05% |
| 机构持股比例 | 42.03% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Hennion & Walsh Asset Management, Inc. | 30 Jun 2026 | 1,847,749 |
| Artia Global Partners Lp | 30 Jun 2026 | 1,806,939 |
| Brown University | 30 Jun 2026 | 1,000,000 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| PEREIRA BRIAN JG | - | 1.42 | -250,000 | -355,000 |
| 累积净数量 | -250,000 | |||
| 累积净值 ($) | -355,000 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 1.42 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PEREIRA BRIAN JG | 董事 | 20 Aug 2026 | 卖 (-) | 222,948 | 1.42 | 316,586 |
| PEREIRA BRIAN JG | 董事 | 20 Aug 2026 | 卖 (-) | 27,052 | 1.42 | 38,414 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合